• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Staphylococcus aureus is a major human pathogen that causes a wide range of clinical
infections. It is a leading cause of bacteremia and infective endocarditis as well as …

Daptomycin (DAP) is a cyclic lipopeptide with in vitro activity against a variety of Gram‐
positive pathogens, including multidrug‐resistant organisms. Since its introduction into …

Daptomycin is a lipopeptide antimicrobial with in vitro bactericidal activity against Gram-
positive bacteria that was first approved for clinical use in 2004 in the United States. Since …

Covering: 2000 to 2018, particularly from 2010 to early 2018 The increase in the incidence
of antibiotic resistant infections is threatening to overwhelm healthcare practices worldwide …

Purpose Guidelines recommend daptomycin combination therapy as an option for
methicillin-resistant Staphylococcus aureus (MRSA) bacteremia after vancomycin failure …

This review is the result of discussions that took place at the 5th MRSA Working Group
Consensus Meeting and explores the possible treatment options available for different types …

Background Daptomycin and ceftaroline (DAP-CPT) have been used for persistent
methicillin-resistant Staphylococcus aureus bacteremia (MRSAB), but have rarely been …

The potency of zinc oxide nanoparticles (NPs), with a core size of~ 7-10 nm, to inhibit
cholera disease was investigated by demonstrating the effect on two biotypes (classical and …

Ceftaroline is approved by the Food and Drug Administration for acute bacterial skin and
skin-structure infections and community-acquired bacterial pneumonia, including cases with …